Physician profile
Michael A Schmidt
NPI 1619945086
$5,251.02
in general payments reported to CMS, 2019-2025
23 companies · $604 in 2025
The $604 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $696 · 2020: $680 · 2021: $775 · 2022: $539 · 2023: $1,010 · 2024: $946 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,560.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $905.51 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $689.68 | 2019-2025 | |
| Abiomed | $669.79 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $438.21 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $271.80 | 2019-2025 | Lifevest |
| Pfizer INC. | $259.12 | 2021-2025 | |
| Medtronic Vascular, INC. | $248.84 | 2019 | |
| Amgen INC. | $237.08 | 2022-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $191.49 | 2022-2024 | Watchman Access System |
| Merck Sharp & Dohme LLC | $182.84 | 2022-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.37 | 2022-2025 | Jardiance |
| Biotronik Nro, INC. | $166.93 | 2024-2025 | Prospera |
| Astrazeneca Pharmaceuticals Lp | $166.14 | 2022-2025 | Farxiga, Wainua |
| Chiesi USA, INC. | $160.67 | 2019-2024 | Cleviprex, Kengreal |
| Medtronic, INC. | $110.05 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $105.32 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $74.33 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $60.32 | 2023-2025 | Assure Wcd |
| Sanofi-Aventis U.S. LLC | $41.14 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.02 | 2025 | |
| Abbott Laboratories | $26.74 | 2023 | Cardiomems |
| Scpharmaceuticals INC. | $24.23 | 2025 | |
| Esperion Therapeutics, INC. | $15.40 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.